Global Pharmaceutical Excipients Market Set To Grow To $8.5bn By 2022

06 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Pharmaceutical Excipients Market Forecast to 2027: Plant-Based, Animal Chemistry, Mineral, Synthetic, Oral Application, Topical Application, Parental Application, Other Application, Binders, Diluents, Glidants, Disintegrant, Others

The pharmaceutical industry is facing various challenges such as patent cliff, strict regulations and reduced healthcare spending; all these factors are hindering the development of new drugs. Novel excipients offer several opportunities to overcome these challenges. Novel excipients can be used to reformulate approved drugs and also improve the quality and safety of the drugs as well as reducing manufacturing cost. Manufacturers of generic drugs are now mainly focusing on reformulating and reintroducing their products with a cost-effective process to develop super generic drugs and to extent patents. Hence, various important steps are taken by key players such as modification in design and dosage forms, increasing focus on quality by design, and use of excipients in reformulation of drugs.
The lead analyst of the report commented “Pharmaceutical industry is highly dependent on the development and discovery of new molecules for the replacement of old drugs revenue stream that are going towards patent expiry. Therefore, drug formulators and innovators are mainly focusing on developing new chemical entities. Similarly, narrow pipeline of new chemical excipients, increasing preference of manufacturers for the direct compression (DC) process and technological advancement in tablets manufacturing, are some of the other factors that will give opportunity for the development of high-functionality excipients.”

Leading companies featured in the report include Evonik Industries AG, BASF SE, Innophos Holdings Inc., The Lubrizol Corporation, The DOW Chemical Company, Wacker Chemie AG, Ashland Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“The colon targeting drug delivery market will grow with exponential growth of 14% over the forecast period from 2020-2030”, says Visiongain

The colon targeting drug delivery market has been used various polymers including biodegradable polymers, guar gum, pectin, chondroitin sulfate, dextran, chitosan, cyclodextrin, inulin, amylose, locust bean gum, and others

23 September 2019

Read

“Global Diagnostic Imaging market set to grow to $32bn by 2024” says Visiongain report

Diagnostic imaging technology such as MRI and CT scans has become more precise and accessible, due to which radiology has increasingly become a key foundation of modern medicine.

20 September 2019

Read

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
Do NOT follow this link or you will be banned from the site!